期刊文献+

样本量及删失率对生存分析模型有效性和偏倚性的影响 被引量:12

The Effect of Sample Size and Censoring Proportion on the Power and Bias of Survival Analysis Models
下载PDF
导出
摘要 目的探讨样本量及删失率对生存分析模型有效性和偏倚性的影响,为根据资料特点选用适合的生存分析方法提供参考依据。方法以实际数据为总体,通过抽样模拟和删失模拟,比较不同样本量和删失率下,Cox模型和加速失效时间模型的有效性和偏倚性及其变化趋势。结果对于大样本(≥500)或删失率较小(≤30%)的数据,两种模型的有效性和偏倚性相近,分析结果均较为可靠。当样本较小(300~400)或删失率较高(40%~60%)时,加速失效时间模型的分析结果更为可靠。结论 Cox模型对于大样本或删失率低的数据更为实用。加速失效时间模型的分析结果在样本量较少或删失率较高时更为可靠。 Objective To explore the effect of sample size and censoring proportion on the power and bias of survival analysis models. To provide the basis of survival analysis models choice based on characteristics of data. Methods Sampling simulation and censoring simulation are used to evaluate the power and bias of Cox model and accelerated failure-time model and their trends at different sample size and censoring proportion. Results For the survival data with more than 500 samples or censoring proportion is less than 30% ,two kinds of models have the similar power and bias and their results are reliable. When the sample size is between 300 and 400 or censoring proportion is between 40% and 60%, accelerated failure-time model is the better choice. Conclusion For the survival data with large sample size and small censoring proportion, Cox model is more practical than accelerated failure-time model, otherwise the accelerated failure-time model is a better choice.
出处 《中国卫生统计》 CSCD 北大核心 2013年第1期5-8,共4页 Chinese Journal of Health Statistics
基金 国家自然科学基金项目(30972552 71173245) 广东省自然科学基金项目(9151008901000023)
关键词 样本量 删失率 生存分析 Sample size Censoring proportion Survivalanalysis
  • 相关文献

参考文献10

  • 1方积乾.生物医学研究中的统计方法[M]北京:高等教育出版社,2007.
  • 2Kay R,Kinnersley N. On the use of the accelerated failure time model as an alternative to the proportional hazards model in the treatment of time to event data:A case study in influenza[J].Drug Information Journal,2002,(03):571-579.
  • 3叶展;顾杏元.Cox模型及其讨论[J]中国卫生统计,1988(03):31-34.
  • 4Ward J,Wayne H,Mattick RP. Role of maintenance treatment in opioid dependence[J].The lanncet,1995,(9148):221-226.
  • 5卫生部;公安部;国家药品监督管理局.海洛因成瘾者社区药物维持治疗试点工作暂行方案[M]北京,2003.
  • 6贾红英,王洁贞,赵敬杰,刘云霞,孔令华,韩梅.几种生存分析参数模型拟合方法及其应用[J].中国卫生统计,2004,21(4):201-203. 被引量:5
  • 7Health Canada. Best Practices-Methadone Maintenance Treatment[M].Ottawa,Her Majesty the Queen in Right of Canada,2002.
  • 8Orbe J,Ferreira E,Nú(n)ez-Antón V. Comparing proportional hazards and accelerated failure time models for survival analysis[J].Statistics in Medicine,2002,(22):3493-3510.doi:10.1002/sim.1251.
  • 9Cox C,Chu HT,Schneider MF. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution[J].Statistics in Medicine,2007,(23):4352-4374.
  • 10徐英,骆福添.生存分析中几种模型的研究概况[J].中国卫生统计,2006,23(4):364-366. 被引量:5

二级参考文献19

  • 1陈家鼎 等.生存数据分析的统计方法[M].北京:中国统计出版社,1998.255-260.
  • 2茆诗松 濮晓龙等(译).寿命数据中的统计模型与方法[M].北京:中国统计出版社,1998..
  • 3叶展 顾杏元.Cox模型及其讨论[J].中国卫生统计,1988,5(3):31-34.
  • 4骆福添 胡孟璇.带时协变的Cox模型及应用[J].中国卫生统计,1988,5:32-35.
  • 5Oakes D.Biometrika centenary:Survival analysis.Biometrika,2001,88:99-142.
  • 6Miller M,Halper J.Regression with censored data.Biometrika,1982,69:521-31.
  • 7Hiller G,Simonoff JS.A comparison of estimators for regression with a censored response variables.Biometrika,1990,77:515-24.
  • 8Lustbader ED.Time-dependent covariates in survival analysis.Biometrika,1980,67:697-710.
  • 9Janez Stare,Frank E Harrell Jr,Harald Heinzl.an S-Plus program to fit linear regression models to censored data using the Buckley-James method.Computer Methods and Programs in Biomedicine,2001,64:45-52.
  • 10Srinivasan C,Mai Zhou.Linear regression with censoring.Journal of multivariate analysis,1994,49:179-201.

共引文献8

同被引文献60

  • 1Rodriguez E, Lilenbaum RC. Small cell lung cancer: past, present, and future [J]. Curr OneolRcp, 2010, 12(5): 327 -334.
  • 2van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small - cell lung cancer [J]. Lancet, 2011, 378(9804): 1741 -1755.
  • 3Stamatis G. Neuroendocrine tumors of the lung: the role of surgery in small cell lung eancer [J]. Thorac Surg Clin, 2014, 24(3) : 313 - 326.
  • 4de Hoyos A, DeCamp MM. Surgery for small cell lung cancer [ J]. Thorac Surg Clin, 2014, 24 (4) : 399 - 409.
  • 5Ploenes T, Osei - Agyemang T, Krohn A, et al. Surgical treatment of early stage small cell lung cancer [ J]. Asian Cardiovasc Thorac Ann, 2012, 20(6) : 694 -698.
  • 6Lee J, Lee J, Choi J, et aL Early treatment volume reduction rate as a prognostic factor in patients treated with chemoradiotherapy for limit- ed stage small cell lung cancer [ J]. Radiat Oncol J, 2015, 33 (2) : 117 - 125.
  • 7Massarelli E, Papadimitrakopoulou Y, Welsh J, et al. Immunothera- py in lung cancer [J]. Transl Lung Cancer Res, 2014, 3(1) :53 - 63.
  • 8Sanchez de Cos Escuin J. Diagnosis and treatment of neuroendocrine lung tumors [ J]. Arch Bronconeumol, 2014, 50 (9) :392 - 396.
  • 9Vallieres E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the path- ologic staging of small cell lung cancer in the forthcoming ( seventh ) edition of the TNM classification for lung cancer [ J]. J Thorac Oncol, 2009, 4(9) : 1049 - 1059.
  • 10Harmsma M, Schutte B, Ramaekers FC. Serum markers in small cell lung cancer: opportunities for improvement [J]. Biochim Biophys Ac- ta, 2013, 1836(2) : 255 -272.

引证文献12

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部